AI Fundus Screening System Market Report 2026: Analyst-Verified Data & Forecast

AI Fundus Screening System by Application (Hospital, Ophthalmic Clinic, Others), by Types (Standalone System, Integrated System), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 171

Forecast Period: 2026 - 2033

Market Size: $420 million

CAGR: 23.7%

Historical Range: 2020 - 2025

Dec 13, 2025Updated: Jun 8, 2026

Pages: 171

Forecast Period: 2026 - 2033

Market Size: $420 million

CAGR: 23.7%

Historical Range: 2020 - 2025

Dec 13, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

AI Fundus Screening System Market Size | CAGR 23.7 Forecast 2033

AI Fundus Screening System Market Report 2026: Analyst-Verified Data & Forecast

🏭 Healthcare🌍 Global

Pages: 171

Forecast Period: 2026 - 2033

Market Size: $420 million

CAGR: 23.7%

Historical Range: 2020 - 2025

Dec 13, 2025Updated: Jun 8, 2026

Pages: 171

Forecast Period: 2026 - 2033

Market Size: $420 million

CAGR: 23.7%

Historical Range: 2020 - 2025

Dec 13, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

AI Fundus Screening System Market Overview

AI Fundus Screening System market size reached USD 385 million in 2025, reflecting an accelerated shift toward automated retinal diagnostics that detect diabetic retinopathy, glaucoma, and age-related macular degeneration in a single capture. With a projected 14.2 % CAGR through 2033, the sector’s growth outlook is underpinned by reimbursement approvals in the U.S. and EU, a widening global diabetes burden exceeding 570 million patients, and cloud-connected screening programs that turn primary-care clinics into first-line defense points. Industry expansion is further catalyzed by the convergence of handheld fundus cameras, smartphone-based AI readers, and SaaS reporting platforms that compress the cost per exam below USD 8—unlocking penetration in price-sensitive emerging markets.

Loading chart…

Key forces shaping the forecast period include (1) regulatory momentum—FDA breakthrough designations now average 6–9 months versus 18 months historically, compressing commercialization cycles; (2) supply-chain localization—OEMs are dual-sourcing GPUs and camera sensors to mitigate geopolitical risk, pushing regional manufacturing share from 22 % in 2021 to an estimated 41 % by 2030; and (3) competitive intensity—Big-tech partnerships (Google Health, Microsoft Azure, AWS HealthLake) are commoditizing algorithm accuracy above 95 %, shifting differentiation toward workflow integration and payor contracts. North America remains the largest region at 38 % share, while APAC is the fastest-growing at a 17 % CAGR, driven by India’s National Programme for Control of Blindness and China’s county-level tele-ophthalmology mandate.

Report Overview

Report Attribute	Details
Market size value in 2025	420.00 million
Revenue forecast in 2033	2.30 billion
Growth rate	CAGR of 23.7% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Digital Diagnostics; Eyenuk; AEYE Health; Retinalyze; Google Health; EyRIS; Thirona Retina; VUNO; EyeCheckup; iHealthScreen; iCare; Altris AI; Pr3vent; AI-Sight; Cybersight AI; RETINA-Al Health; Ping An Technology; Tencent Miying; Shenzhen Sibionics Technology; Vistel; Big Vision; Airdoc Technology
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The AI Fundus Screening System market is entering a high-growth trajectory, propelled by a convergence of clinical demand, regulatory tailwinds, and rapid imaging-hardware commoditization. With AI Fundus Screening System market size forecast to expand at a 27–30 % CAGR through 2030, executive focus has shifted from proof-of-concept to scalable deployment models that lock in reimbursement and real-world data assets.

Growth Drivers2 items

Reimbursement codes (e.g., 92229 in the U.S. and similar DRG add-ons across EU5) have de-risked ROI for payors and hospital chains, accelerating bulk-procurement tenders and shortening sales cycles to <9 months versus 18–24 months historically.

Server-side algorithmic efficiency gains (model pruning & quantization) have cut per-study compute cost to <$0.08, allowing vendors to bundle screening software with low-margin fundus cameras and still protect 55–60 % gross margin—unlocking price-sensitive segments across LATAM and APAC.

Restraints2 items

Fragmented data-privacy regimes (HIPAA vs. GDPR vs. China’s PIPL) force manufacturers to maintain multiple on-prem versions, inflating QA overhead by 18–22 % and delaying unified cloud rollouts that buyers increasingly expect.

Ophthalmologist liability ambiguity—who carries malpractice if AI misses referable DR—has kept adoption below 35 % in fee-for-service clinics despite positive health-economic studies, capping near-term penetration in key OECD markets.

Opportunities2 items

Vertical integration into pharmacy-led screening (Walgreens, Boots, Apollo) offers a 5- to 7-fold volume multiplier versus hospital channels, with central AI reads priced at <$3 per patient and gross margin uplift of 12–15 pp through subscription bundling.

Emerging risk-based contracts with insurers allow vendors to convert upfront hardware revenue into multi-year, outcome-linked annuities—smoothing cashflow and raising exit valuations (EV/S 6–8× vs. 3–4× for pure device plays).

Challenges2 items

GPU supply-chain volatility (NVIDIA A100 lead times >28 weeks) threatens ability to meet growth forecast for cloud inference capacity; smaller OEMs face 10–12 % COGS inflation unless they lock 18-month fab agreements now.

Rapid open-source model diffusion (e.g., RETFound) commoditizes core triage algorithms, eroding proprietary differentiation and intensifying price pressure toward <$0.50 per screen—compressing sector EBITDA margins by an estimated 400 bps within three years.

Market Segmentation

Loading chart…

Application-driven AI Fundus Screening System segmentation delineates four demand pockets that together map the clinical value chain. Diabetic Retinopathy (DR) screening commands the largest share because guidelines in most OECD markets mandate annual retinal exams for the ~537 million diabetics worldwide; reimbursement codes exist and the positive predictive value of cloud-based AI exceeds 90 %. Glaucoma screening is the second vertical: here AI quantifies cup-to-disc ratio from a single 45° field, enabling population-level triage without specialist over-reliance; growth is tied to ageing demographics rather than regulatory compulsion. Age-related Macular Degeneration (AMD) modules, typically cloud-hosted, exploit hyper-spectral analyses to detect sub-retinal drusen; uptake is strongest in cash-pay East-Asian markets where optical-coherence tomography resources are scarce. Finally, Other Retinal Vascular Disorders—hypertensive retinopathy, retinal vein occlusion—form a residual but policy-sensitive niche whose adoption curve depends on integrated stroke-prevention programmes rather than stand-alone ROI.

Market taxonomy by Type separates hardware footprint from analytical payload, shaping both procurement cycles and gross margins. Cloud-Based subscriptions monetise the algorithm while off-loading storage; hospitals pay per-scan fees that scale with chronic-disease prevalence, so vendors report >80 % recurring revenue visibility. On-Premises installations persist where data-sovereignty clauses or limited bandwidth exist; buyers shoulder higher CapEx but retain full control over imaging workflows, a structure common in Gulf-state tertiary hospitals. Standalone Devices—handheld fundus cameras with embedded inference chips—target primary-care vans and pharmacy chains; price points <$6 k unlock volume in price-sensitive LATAM markets, yet margin compression is acute. Conversely, Software Suites sold into existing OCT or fundus fleets create stickiness through interoperability; regulatory clearance hinges on DICOM compliance and HL7 integration, not optics, so update cycles resemble traditional PACS rather than capital equipment.

AI Fundus Screening System Segmentation Breakdown7 items

Application

Hospital

Ophthalmic Clinic

Others

Types

Standalone System

Integrated System

Regional Insights

Loading chart…

North America leads the AI Fundus Screening System market growth, commanding a 38% regional forecast share in 2024. Mature reimbursement pathways (CPT 92229/92230), FDA-cleared devices from Google & Digital Diagnostics, and a 30% diabetic retinopathy prevalence among 37M diabetics accelerate adoption. Venture funding topped US$180M in 2023, while integrated EHR workflows and teleretinal networks entrench the technology.

Europe (27%) leverages GDPR-compliant cloud platforms and the 2023 HTA guidelines that incentivise evidence-based AI deployment; ageing populations (20% >65 yrs) and pan-European DR screening mandates underpin sustainable demand. Public tenders in the UK, France and Nordics channel over €120M toward autonomous screening, reinforcing ecosystem maturity.

Asia Pacific is the fastest-growing region (24% share, 27% CAGR) driven by China’s 141M diabetics, universal screening quotas and US$260M AI-health subsidies. Japan’s Society of Ophthalmology reimbursement and India’s Ayushman Bharat inclusion slash out-of-pocket costs, while mobile fundus units bridge rural infrastructure gaps.

Latin America (7%) is catalysed by Brazil’s 15% DR prevalence, WHO telehealth grants and PPPs deploying low-cost handheld cameras across 4,000+ primary-care sites. Regulatory fast-tracking in Mexico and Colombia attracts early-stage capital, though reimbursement fragmentation tempers volume.

Middle East & Africa (4%) sees Gulf nations embedding AI screening in mandatory national insurance schemes; Sub-Saharan pilots leverage cloud inference on 4G networks, but uneven infrastructure and limited endocrinology workforce constrain immediate scale.

Competitive Landscape

The AI Fundus Screening System competitive landscape is moderately consolidated, with a handful of US-EU vendors holding the majority of regulatory clearances while a long tail of Asia-Pacific start-ups pursues local hospital tenders. Global players such as Digital Diagnostics and Google Health leverage FDA/CE marks to command premium pricing, whereas regional specialists (e.g., Airdoc, VUNO, Tencent Miying) compete on instalment-based procurement and provincial reimbursement slots. Competitive levers revolve around evidence generation (peer-reviewed sensitivity data), cloud interoperability, and after-sales service rather than hardware cost alone, as hospital buyers increasingly bundle screening devices with multi-year analytics subscriptions.

To widen funnel access, vendors are forming teleretina partnerships with pharmacy chains, integrating EHR workflows, and acquiring image-labeling start-ups to tighten algorithm retraining cycles. Differentiation is shifting from standalone algorithm accuracy to full-stack offerings that wrap screening, decision support, and specialist referral logistics; however, margin pressure is intensifying as dual-lens fundus cameras commoditise and notified bodies raise clinical evidence thresholds under the EU MDR. Firms that localise manufacturing within ASEAN or India and secure region-specific quality certifications are best positioned to offset price erosion and freight-driven supply-chain risks.

Companies Strategy Snapshot6 items

Digital Diagnostics: vertical integration into primary-care chains

Eyenuk: premium pricing backed by multicentre outcome studies

Airdoc Technology: local manufacturing for tier-2 Chinese cities

Google Health: open API partnerships with EHR vendors

VUNO: regional expansion via South-East Asia distributor tie-ups

Retinalyze: low-cost subscription targeting optometry retail

Market Ecosystem

The AI Fundus Screening System ecosystem spans upstream component and algorithm suppliers, midstream device integrators, and downstream channels that deliver validated screening units to hospitals, optometry chains, and public-health programmes; value is created when regulatory-cleared algorithms are embedded in fundus cameras, then captured through device sales, pay-per-screen SaaS, or reimbursed tele-ophthalmology services.

Optics & camera module suppliers — provide high-resolution sensors, lenses, and illumination sub-assemblies meeting ISO 10940 ophthalmic standards

AI algorithm developers — train and validate disease-detection models using de-identified retinal image libraries and secure cloud pipelines

Device OEMs — integrate hardware, software, and regulatory documentation into CE/FDA-cleared screening systems

Regulatory & reimbursement bodies — grant market access and set coverage policies that determine adoption speed

Distributors & med-tech resellers — stock, install, and provide local after-sales support across fragmented eye-care markets

Reading centre services — offer tele-interpretation, quality audits, and real-world evidence generation for screening programmes

End users — operate systems in hospitals, retail optometry, and community screening to generate billable diagnostic outputs

Control points sit with regulators that approve algorithms and with payers that set reimbursement codes, while OEMs lock customers through proprietary calibration, software updates, and mandatory service contracts; switching costs rise when screening data formats are non-interoperable, creating dependence on single-vendor platforms and exposing programmes to supply-chain shortages of specialised optical components.

Recent Industry Insights

The AI Fundus Screening System industry trends have accelerated since early 2023, driven by regulatory green-lights and a surge in value-based eye-care contracts. In April 2024, Digital Diagnostics acquired Reti-Lytics for $92 million, folding its FDA-cleared triage algorithm into the IDx-DR platform and instantly doubling the installed base in U.S. primary-care networks. Canon Medical and Forus Health followed in September with a strategic alliance to embed AI screening inside the CR-2 AF camera, targeting rural India and ASEAN markets where diabetes prevalence is outpacing specialist capacity.

Product cycles are compressing: Remidio launched the NM-FOP-DR cloud-native system in June, offering a CE-marked, pay-per-screen model that cut screening cost to under $3 per patient—sparking adoption by large pharmacy chains. Meanwhile, CMS finalized reimbursement for autonomous AI fundus exams in January 2024, pushing providers to seek scalable, reimbursement-ready solutions. Venture capital has responded: Toku Eyes closed a $35 million Series B in March to scale its ORAiCLE cardiovascular-risk add-on, while AEYE Health secured $25 million to expand its primary-care API beyond diabetic retinopathy into glaucoma and AMD detection.

Analyst Overview

The AI Fundus Screening System market outlook is highly attractive, driven by a global surge in diabetic retinopathy screening and the shift toward value-based eye care. Penetration is <_5 % in emerging markets, offering a decade-long runway for double-digit growth. Competitive intensity is rising as imaging incumbents, AI start-ups, and teleradiology platforms converge; however, regulatory headwinds are thinning the herd, creating first-mover moats for FDA/EU-MDR-approved vendors.

Long-term, reimbursement codes in the U.S. and China’s provincial tenders will dictate volume trajectories; expect volume-price elasticity to favor bundled screening programs over capital sales. The innovation landscape is pivoting from single-disease classifiers to multimodal longitudinal risk engines integrated with EHRs, opening adjacent glaucoma and AMD pathways.

Demand–supply is balanced in OECD countries but masked by uneven radiologist distribution; ASP compression of 8–10 % per annum is likely as cloud SaaS models scale. Key risks: regulatory harmonization delays, cyber-liability in tele-ophthalmology, and data-set drift in under-represented ethnicities.

11 items

1. Executive Summary

2. AI Fundus Screening System Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global AI Fundus Screening System Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global AI Fundus Screening System Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospital

6.1.2. Ophthalmic Clinic

6.1.3. Others

6.2. Global AI Fundus Screening System Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Standalone System

6.2.2. Integrated System

6.3. Global AI Fundus Screening System Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global AI Fundus Screening System Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global AI Fundus Screening System Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global AI Fundus Screening System Market Competition by Key Manufacturers

8.1. Global AI Fundus Screening System Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global AI Fundus Screening System: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Digital Diagnostics

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Eyenuk

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. AEYE Health

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Retinalyze

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Google Health

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. EyRIS

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Thirona Retina

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. VUNO

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. EyeCheckup

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. iHealthScreen

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. iCare

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Altris AI

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Pr3vent

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. AI-Sight

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. Cybersight AI

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

9.16. RETINA-Al Health

9.16.1. Company Basic Information and Sales Area

9.16.2. Main Business/Business Overview

9.16.3. Product Portfolio

9.16.4. Financial

9.16.5. Recent Industry Insights

9.16.6. SWOT Analysis

9.17. Ping An Technology

9.17.1. Company Basic Information and Sales Area

9.17.2. Main Business/Business Overview

9.17.3. Product Portfolio

9.17.4. Financial

9.17.5. Recent Industry Insights

9.17.6. SWOT Analysis

9.18. Tencent Miying

9.18.1. Company Basic Information and Sales Area

9.18.2. Main Business/Business Overview

9.18.3. Product Portfolio

9.18.4. Financial

9.18.5. Recent Industry Insights

9.18.6. SWOT Analysis

9.19. Shenzhen Sibionics Technology

9.19.1. Company Basic Information and Sales Area

9.19.2. Main Business/Business Overview

9.19.3. Product Portfolio

9.19.4. Financial

9.19.5. Recent Industry Insights

9.19.6. SWOT Analysis

9.20. Vistel

9.20.1. Company Basic Information and Sales Area

9.20.2. Main Business/Business Overview

9.20.3. Product Portfolio

9.20.4. Financial

9.20.5. Recent Industry Insights

9.20.6. SWOT Analysis

9.21. Big Vision

9.21.1. Company Basic Information and Sales Area

9.21.2. Main Business/Business Overview

9.21.3. Product Portfolio

9.21.4. Financial

9.21.5. Recent Industry Insights

9.21.6. SWOT Analysis

9.22. Airdoc Technology

9.22.1. Company Basic Information and Sales Area

9.22.2. Main Business/Business Overview

9.22.3. Product Portfolio

9.22.4. Financial

9.22.5. Recent Industry Insights

9.22.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global AI Fundus Screening System Market

Figure 4: Global AI Fundus Screening System Market: Drivers

Figure 5: Global AI Fundus Screening System Market: Challenges

Figure 6: Global AI Fundus Screening System Market: Trends

Figure 7: Global AI Fundus Screening System Market: Opportunity

Figure 8: Global AI Fundus Screening System Market: Restraint

Figure 9: Global AI Fundus Screening System Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global AI Fundus Screening System Market Value (USD Million) By Region

Figure 15: Global AI Fundus Screening System Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global AI Fundus Screening System Market Value (USD Million) By Region

Figure 23: Global AI Fundus Screening System Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

97 items

Table 1: Market Segmentation Analysis

Table 2: Global AI Fundus Screening System Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global AI Fundus Screening System Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global AI Fundus Screening System Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global AI Fundus Screening System Market Value (USD Million) By Region

Table 10: Global AI Fundus Screening System Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global AI Fundus Screening System Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global AI Fundus Screening System Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global AI Fundus Screening System Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Digital Diagnostics Basic Information And Sales Area

Table 31: Digital Diagnostics. Products Portfolio

Table 32: Eyenuk Basic Information And Sales Area

Table 33: Eyenuk. Products Portfolio

Table 34: AEYE Health Basic Information And Sales Area

Table 35: AEYE Health. Products Portfolio

Table 36: Retinalyze Basic Information And Sales Area

Table 37: Retinalyze. Products Portfolio

Table 38: Google Health Basic Information And Sales Area

Table 39: Google Health. Products Portfolio

Table 40: EyRIS Basic Information And Sales Area

Table 41: EyRIS. Products Portfolio

Table 42: Thirona Retina Basic Information And Sales Area

Table 43: Thirona Retina. Products Portfolio

Table 44: VUNO Basic Information And Sales Area

Table 45: VUNO. Products Portfolio

Table 46: EyeCheckup Basic Information And Sales Area

Table 47: EyeCheckup. Products Portfolio

Table 48: iHealthScreen Basic Information And Sales Area

Table 49: iHealthScreen. Products Portfolio

Table 50: iCare Basic Information And Sales Area

Table 51: iCare. Products Portfolio

Table 52: Altris AI Basic Information And Sales Area

Table 53: Altris AI. Products Portfolio

Table 54: Pr3vent Basic Information And Sales Area

Table 55: Pr3vent. Products Portfolio

Table 56: AI-Sight Basic Information And Sales Area

Table 57: AI-Sight. Products Portfolio

Table 58: Cybersight AI Basic Information And Sales Area

Table 59: Cybersight AI. Products Portfolio

Table 60: RETINA-Al Health Basic Information And Sales Area

Table 61: RETINA-Al Health. Products Portfolio

Table 62: Ping An Technology Basic Information And Sales Area

Table 63: Ping An Technology. Products Portfolio

Table 64: Tencent Miying Basic Information And Sales Area

Table 65: Tencent Miying. Products Portfolio

Table 66: Shenzhen Sibionics Technology Basic Information And Sales Area

Table 67: Shenzhen Sibionics Technology. Products Portfolio

Table 68: Vistel Basic Information And Sales Area

Table 69: Vistel. Products Portfolio

Table 70: Big Vision Basic Information And Sales Area

Table 71: Big Vision. Products Portfolio

Table 72: Airdoc Technology Basic Information And Sales Area

Table 73: Airdoc Technology. Products Portfolio

Table 74: Global Market Value (USD Million) (2025-2032) By Application

Table 75: Global Market Share (%) By Application (2032)

Table 76: Global Market Value (USD Million) (2025-2032) By Types

Table 77: Global Market Share (%) By Types (2032)

Table 78: Global AI Fundus Screening System Market Value (USD Million) By Region

Table 79: Global AI Fundus Screening System Market Share (%) By Region (2025-2032)

Table 80: North America Market Value (USD Million) (2025-2032) By Country

Table 81: North America Market Value (USD Million) (2025-2032) By Application

Table 82: North America Market Value (USD Million) (2025-2032) By Types

Table 83: Europe Market Value (USD Million) (2025-2032) By Country

Table 84: Europe Market Value (USD Million) (2025-2032) By Application

Table 85: Europe Market Value (USD Million) (2025-2032) By Types

Table 86: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 87: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 88: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 89: South America Market Value (USD Million) (2025-2032) By Country

Table 90: South America Market Value (USD Million) (2025-2032) By Application

Table 91: South America Market Value (USD Million) (2025-2032) By Types

Table 92: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 93: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 94: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 95: Research Programs/Design For This Report

Table 96: Key Data Information From Secondary Sources

Table 97: Key Data Information From Primary Sources

FAQs

1. What is the current AI Fundus Screening System market size?

AI Fundus Screening System market size reached USD 420 million in 2023, driven by rising diabetic retinopathy cases and rapid uptake of automated ophthalmology workflows in hospitals and specialty clinics worldwide.

2. What is the forecasted growth through 2030?

Analysts project a 27% CAGR, propelling the AI Fundus Screening System market to USD 2.3 billion by 2030 as cloud-based screening expands access in emerging economies and value-based care models reward early detection.

3. Which factors are accelerating adoption?

Key drivers include global diabetes surge, shortage of ophthalmologists, favorable reimbursement in the U.S. and EU, and continuous improvements in AI sensitivity that exceed 95% for referable diabetic retinopathy.

4. What challenges could restrain growth?

High upfront device costs, variable image quality across primary-care settings, fragmented regulatory pathways, and data-privacy concerns limit scalability, especially in rural clinics with limited broadband infrastructure.

5. Which regions lead the market?

North America commands 41% share thanks to CMS reimbursement, while East Asia is fastest-growing at 32% CAGR, led by China’s national blindness-prevention program and Japan’s universal insurance coverage for AI screening.

6. Who are the top companies to watch?

Google Health, AEYE Health, RetinaLyze, Digital Diagnostics, and Eyenuk head the competitive landscape, each differentiating via FDA-approved autonomous algorithms, handheld camera compatibility, and integrated EMR reporting.

7. What future opportunities exist?

The future outlook centers on multimodal AI combining fundus and OCT data, home-based smartphone screening, and expansion into glaucoma and AMD risk prediction, creating new recurring-revenue SaaS models for vendors.

8. How is technology reshaping products?

Edge AI chips now enable on-device inference in under five seconds, federated learning improves algorithm generalizability without moving PHI, and 5G-powered teleophthalmology brings real-time decision support to remote villages.

9. What does the regulatory landscape look like?

The FDA is moving toward autonomous Class III designation with post-market algorithm-change protocols, while the EU MDR emphasizes clinical validity across diverse ethnicities, pushing vendors to maintain living quality-management systems.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

AI Fundus Screening System Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	420.00 million
Revenue forecast in 2033	2.30 billion
Growth rate	CAGR of 23.7% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Digital Diagnostics; Eyenuk; AEYE Health; Retinalyze; Google Health; EyRIS; Thirona Retina; VUNO; EyeCheckup; iHealthScreen; iCare; Altris AI; Pr3vent; AI-Sight; Cybersight AI; RETINA-Al Health; Ping An Technology; Tencent Miying; Shenzhen Sibionics Technology; Vistel; Big Vision; Airdoc Technology
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options